Search results
Added:
10 months ago
Explore ESC 25 Top Trials with Insights from the Thoraxcenter!Join Prof Nicolas Van MieghemandDr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025.In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research…
View more
Added:
11 months ago
Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.ESC Congress 2025 Hot Line Trials Discussed:00:25 DOUBLE-CHOICE03:03 VANTAGE05:03 VICTOR06:28 VICTORIA07:58 DIGIT HF10:19 DAPA ACT HF-TIMI…
View more
Added:
3 months ago
ACC 2026 - Two randomised trials position TriClip TEER as a transformative option in TR, delivering significant reductions in heart failure hospitalisations and supporting earlier intervention in clinical practice.Prof Erwan Donal (Hospital Pontchaillou of Rennes, Rennes, FR) joins us on-site at ACC 2026 to share the findings from two randomised trials (Tri.Fr and TRILUMINATE Pivotal)…
View more
Added:
1 year ago
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference…
View more
Added:
10 months ago
ESC Congress 2025 - The opening day of ESC Congress 2025 delivered compelling new developments as updated clinical practice guidelines were released alongside a series of eagerly awaited Hot Line trials.Leading interventional cardiologists, Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) present focused overviews of the most significant Hot Line and Late…
View more
Added:
1 year ago
Unpack ACC.25's Top Trials with View from the Thoraxcenter!Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC 2025.In this thought-provoking ACC 2025 wrap-up, delve into the nuances of the most impactful trials, gaining insights into their implications for current practice and future research directions.00:36 -…
View more
Added:
1 year ago
ESC Congress 24 – Day 2 of the ESC Congress 2024 was packed with important data for cardiovascular practice.Interventional experts DrMirvat Alasnagand DrKhaled Al-Shaibi(King Fahd Armed Forces Hospital, SA) joined us to summarise the key take-home messages from hot line trials presented on day.Day 2 Highlights:00:24-03:02: NOTION-3: Percutaneous coronary intervention in patients undergoing…
View more
Added:
1 year ago
In this exclusive episode of the "Innovations in Cardiology" podcast series, host Dr Dipti Itchhaporia, past president of the American College of Cardiology, delves into the latest advancements in cardiovascular health. She is joined by Dr Valentin Fuster, a pioneer in the field, who shares invaluable insights into the impact of biological ageing, the connection between the heart and brain, and…
View more
Added:
3 months ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in…
View more
Added:
1 month ago
HFA Congress 2026 — Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) joins us to discuss findings from the UF-CARE trial, evaluating ultrafiltration against enhanced medical therapy in patients with type 2 cardiorenal syndrome.This randomised, open-label study enrolled patients with severe, refractory heart failure and concurrent chronic kidney disease, a population with a high…
View more